<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03391804</url>
  </required_header>
  <id_info>
    <org_study_id>ALLN-177-206</org_study_id>
    <secondary_id>2017-003547-38</secondary_id>
    <nct_id>NCT03391804</nct_id>
  </id_info>
  <brief_title>Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia</brief_title>
  <official_title>Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of ALLN-177 in reducing plasma and urinary oxalate levels in
      adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary
      hyperoxaluria
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2, multi-center, open label, single arm study to evaluate the effect and safety of
      ALLN-177 in adult and pediatric patients aged 12 and older with enteric hyperoxaluria and
      hyperoxalemia or primary hyperoxaluria .

      Approximately 15-20 evaluable subjects are planned to be enrolled in the study. Eligible
      subjects will administer ALLN-177 with each meal/snack 5 times per day for 12 consecutive
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma oxalate</measure>
    <time_frame>on 12 weeks of treatment</time_frame>
    <description>Efficacy will be assessed based on change from baseline in plasma oxalate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hr urinary oxalate excretion</measure>
    <time_frame>on 12 weeks of treatment</time_frame>
    <description>Efficacy will be assessed based on change from baseline in 24-hr urinary oxalate excretion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Enteric Hyperoxaluria</condition>
  <condition>Primary Hyperoxaluria</condition>
  <condition>Hyperoxalemia</condition>
  <arm_group>
    <arm_group_label>ALLN-177</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALLN-177 7,500 units (2 capsules)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLN-177</intervention_name>
    <description>ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks</description>
    <arm_group_label>ALLN-177</arm_group_label>
    <other_name>Oxalate decarboxylase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed a informed consent form or an assent

          2. Aged 12 or older with body weight ≥ 35kg

          3. History of primary hyperoxaluria or enteric hyperoxaluria associated with a known
             underlying enteric disorder associated with malabsorption (e.g., bariatric surgery,
             Crohn's disease, short bowel syndrome, or other malabsorption syndrome)

          4. Urinary oxalate ≥ 40mg/24h (normalized for body surface area in children) at Screening
             in patients with eGFR &gt;15 mL/min/1.73m2

          5. In patients with enteric hyperoxaluria, eGFR &lt; 45mL/min/1.73m2 at Screening

          6. In patients with enteric hyperoxaluria, plasma oxalate &gt; 5µmol/L at Screening

          7. Patients on dialysis, must be stable for greater than 3 months

        Exclusion Criteria:

        1. Unable or unwilling to discontinue Vitamin C supplementation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annamaria Kausz, MD MS</last_name>
    <role>Study Director</role>
    <affiliation>Allena Pharmaceuticals Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Berlin-Mitte, Medizinische Klinik mit Schwepunkt Nephrologie und Internistische Intensivmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellcome Trust Clinical Research Facility</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7 DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxalate</keyword>
  <keyword>Kidney Stones</keyword>
  <keyword>oxalate nephropathy</keyword>
  <keyword>systemic oxalosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

